What they say:
A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March 2013 issue of Nature, by Prof Dimmler, Boon, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for Myocardial Infarction: Kaempferol-3-O-rutinoside, isolated from Solidago virgaurea – European Goldenrod, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS
[easy_payment currency=”USD”]
From Significance of the study to Public Health relevance:
Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) out of 55 million deaths that occur every year, nearly 18.33 million deaths are due to cardiovascular causes; (3) the raise of death rate, due to cardiovascular disease, has increased from 123 lakhs in 1990 to 173 lakhs in 2013; (4) 85% of people over 80 years are susceptible to cardiovascular diseases;(5) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (6) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (7) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; and (8) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year from 2030 onwards, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free natural product-based drug.
From Research Findings to Therapeutic Opportunity:
This study provides a natural product-based therapy for myocardial infarction.
Figure 1. Kaempferol-3-O-rutinoside functions as a Cardioprotective agent. Mechanistic insights into how Kaempferol-3-O-rutinoside induces the expression of PNUTS and Telomerase to prevent myocardial infarction and promote Cardiac regeneration/survival
Kaempferol-3-O-rutinoside, by increasing the expression of their target genes, it may increase the expression of PNUTS (fig.1). Thereby, it may: (1) inhibit DNA damage responses, (2) increase telomerase expression, (3) inhibit telomere shortening; (4) promote cardiomyocyte survival/regeneration; (5) decelerate ageing; and (6) extend life span (fig 1).
Thus, by treating patients with Kaempferol-3-O-rutinoside, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing “Kaempferol-3-O-rutinoside or its analogs, either alone or in combination with other drugs” may be used to improve cardiac function after myocardial infarction (fig. 3).
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How Kaempferol-3-O-rutinoside increases the expression of PNUTS/Telomerase
Amount: $300#
# Research cooperation
For purchase and payment details, you may reach us at admin@genomediscovery.org
References:
Web:http://genomediscovery.org or http://newbioideas.com/
Citation: Boominathan, L., Natural product-derived therapy for Myocardial Infarction: Kaempferol-3-O-rutinoside, isolated from Solidago virgaurea – European Goldenrod, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS, 29/October/2017, 9.16 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at admin@genomediscovery.org